Opportunity Information: Apply for RFA AG 13 013
Apply for RFA AG 13 013
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Dec 12, 2012 and posted on Oct 15, 2012.
- Applicants must submit their applications by Jan 14, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $23,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: Private institutions of higher education Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Small businesses City or township governments Special district governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) State governments County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity "Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01)" (Funding Opportunity Number: RFA-AG-13-013) is a discretionary research grant designed to push Alzheimers disease (AD) therapeutics forward by funding integrative, team-based projects that can uncover and validate new drug targets. The central emphasis is on going beyond single-gene or single-pathway hypotheses and instead identifying promising intervention points within broader molecular networks that contribute to AD across different phases of disease development and progression. In practice, this means applicants are expected to use interdisciplinary approaches that connect biology, genetics, systems-level network analysis, and preclinical experimentation to find targets that are not only scientifically interesting but also realistically actionable for therapy development.
A defining feature of this opportunity is its explicit encouragement of team science through the multiple Program Director/Principal Investigator (PD/PI) option. NIH is signaling that the scope of work needed to discover novel targets in complex AD-related networks, and then validate those targets in preclinical settings, typically requires more than one lab and more than one area of expertise. Competitive applications would therefore be expected to show clear integration among disciplines, such as combining computational or systems biology methods for network-based target discovery with rigorous experimental validation in relevant cellular or animal models, and potentially adding medicinal chemistry, biomarker strategy, or translational pharmacology expertise where appropriate. The goal is not just to generate lists of candidate genes or proteins, but to build a coherent case that a target sits in a disease-relevant network, can be modulated, and produces meaningful effects in preclinical testing.
The scientific scope centers on "identification and preclinical validation" of novel therapeutic targets tied to molecular networks involved in different stages of AD pathogenesis. That framing suggests projects may address early initiating events, intermediate disease propagation mechanisms, or later-stage neurodegeneration and functional decline, as long as the work is anchored in network biology and includes a credible plan for preclinical validation. The opportunity is categorized under Health and uses CFDA 93.866 (Aging Research), reflecting administration through NIH with relevance to aging and neurodegenerative disease.
From an administrative standpoint, this is an R01 grant mechanism with an award ceiling of $1,000,000, and the program anticipated an estimated total funding level of $23,000,000. There is no cost-sharing or matching requirement. Key dates show it was posted October 15, 2012, with the original closing date of January 13, 2013 and a current closing date of January 14, 2013, and it was archived February 14, 2013. Although archived opportunities are no longer open for submission, the details remain useful as a model for the types of research NIH sought to stimulate at the time and for understanding how NIH frames network-based target discovery and validation in AD.
Eligibility is broad and inclusive, spanning public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (other than small businesses), and small businesses, along with a wide range of government entities (state, county, city or township, special district governments, and certain school districts). The eligibility list also explicitly includes tribal governments and tribal organizations, public housing and Indian housing authorities, and a range of mission-focused institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities (TCCUs). Notably, non-U.S. entities are eligible as well: foreign organizations and foreign institutions may apply, non-domestic components of U.S. organizations are eligible, and foreign components (as defined by NIH policy) are allowed. Faith-based and community-based organizations are also included among eligible applicants, reflecting NIH policy that eligibility is based on capacity to conduct the proposed research rather than institutional type.
The sponsoring agency is the National Institutes of Health. Applicants who needed help accessing the announcement or who encountered linking issues were directed to the NIH Office of Extramural Research (OER) webmaster contact. The full announcement was referenced via an NIH grants guide link (http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-013.html), which would have contained the complete requirements and review considerations, including expectations for the multi-PI leadership plan and the specifics of what NIH considered adequate preclinical validation for proposed targets.
FAQs: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01)
What is the official title of this NIH funding opportunity?
The opportunity is titled "Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01)."
What is the Funding Opportunity Number?
The Funding Opportunity Number is RFA-AG-13-013.
Which agency sponsors this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What type of grant mechanism is used?
This opportunity uses the NIH R01 research project grant mechanism.
What is the main goal of the program?
The central goal is to move Alzheimers disease (AD) therapeutics forward by funding integrative, team-based projects that identify and preclinically validate novel therapeutic targets. The emphasis is on targets that are actionable for therapy development, not just scientifically interesting.
What does NIH mean by an "interdisciplinary" approach in this announcement?
Based on the description provided, interdisciplinary means connecting multiple areas such as biology, genetics, systems-level/network analysis, and preclinical experimentation. Competitive projects are expected to integrate these disciplines rather than pursuing isolated, single-discipline work.
Why does this opportunity emphasize molecular networks instead of single genes or single pathways?
The program is explicitly designed to go beyond single-gene or single-pathway hypotheses. It seeks intervention points within broader molecular networks that contribute to AD across different phases of disease development and progression.
What kinds of research activities does the scientific scope support?
The scientific scope centers on the "identification and preclinical validation" of novel therapeutic targets linked to molecular networks involved in different stages of AD pathogenesis.
Which stages of Alzheimers disease can a project focus on?
Projects may address early initiating events, intermediate disease propagation mechanisms, or later-stage neurodegeneration and functional decline, as long as the work is anchored in network biology and includes a credible plan for preclinical validation.
What does "preclinical validation" imply in the context of this opportunity?
The description indicates NIH is looking for rigorous experimental validation in relevant cellular or animal models, supporting a coherent case that a target is disease-relevant, can be modulated, and produces meaningful effects in preclinical testing.
Is it enough to generate a list of candidate genes or proteins?
No. The opportunity emphasizes that the goal is not simply to produce lists of candidate genes or proteins. Applicants are expected to build a coherent case that connects a target to a disease-relevant network and demonstrates actionable potential through preclinical validation.
Does this funding opportunity encourage team science or multiple laboratories?
Yes. A defining feature is the explicit encouragement of team science through the multiple Program Director/Principal Investigator (PD/PI) option, reflecting NIHs view that discovery and validation across complex AD-related networks often requires multiple labs and areas of expertise.
What is the multiple PD/PI option?
The announcement explicitly encourages using more than one Program Director/Principal Investigator (PD/PI). This is intended to support integrated, team-based leadership across disciplines needed for network-based target discovery and validation.
What kinds of expertise does NIH suggest could be part of a competitive team?
Examples described include combining computational or systems biology methods for network-based target discovery with experimental validation in cellular or animal models, and potentially adding medicinal chemistry, biomarker strategy, or translational pharmacology expertise where appropriate.
What is the award ceiling for this R01 opportunity?
The award ceiling is $1,000,000.
What was the estimated total funding level anticipated for the program?
The program anticipated an estimated total funding level of $23,000,000.
Is cost-sharing or matching required?
No. The opportunity states there is no cost-sharing or matching requirement.
What is the CFDA number and program area?
The opportunity is categorized under Health and uses CFDA 93.866 (Aging Research).
When was the opportunity posted?
It was posted on October 15, 2012.
What were the closing dates?
The original closing date was January 13, 2013, and the current closing date was January 14, 2013.
Is this funding opportunity still open?
No. It was archived on February 14, 2013, and archived opportunities are no longer open for submission.
If it is archived, why are the details still useful?
The description notes that, while it is no longer open, it remains useful as a model for the types of research NIH sought to stimulate and for understanding how NIH frames network-based target discovery and validation in Alzheimers disease.
Who is eligible to apply?
Eligibility is described as broad, including public and private institutions of higher education, nonprofit organizations (501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and multiple types of government entities (including state, county, city or township, special district governments, and certain school districts).
Are tribal governments and tribal organizations eligible?
Yes. The eligibility list explicitly includes tribal governments and tribal organizations.
Are public housing authorities eligible?
Yes. Public housing and Indian housing authorities are included among eligible applicants.
Are minority-serving institutions specifically included?
Yes. The eligibility list explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are included among eligible applicants.
Can non-U.S. organizations apply?
Yes. Foreign organizations and foreign institutions may apply. The description also states that non-domestic components of U.S. organizations are eligible and that foreign components (as defined by NIH policy) are allowed.
Where was the full announcement referenced?
The full announcement was referenced via the NIH grants guide link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-013.html
Who was listed as a contact for help accessing the announcement or fixing link issues?
Applicants needing help accessing the announcement or encountering linking issues were directed to the NIH Office of Extramural Research (OER) webmaster contact.
What types of expectations would likely be detailed in the full announcement?
The description indicates the full announcement would contain complete requirements and review considerations, including expectations for the multi-PI leadership plan and details on what NIH considered adequate preclinical validation for proposed targets.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Sea based Aviation National Naval Responsibility Propulsion Focus Area
Previous opportunity: Regional Climate Change Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 13 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 13 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alzheimers Disease Prevention Trials (R01) Apply for RFA AG 13 015 Funding Number: RFA AG 13 015 Agency: National Institutes of Health Category: Health Funding Amount: $4,500,000 |
| Alzheimers Disease Phase I Clinical Trials (R01) Apply for RFA AG 13 016 Funding Number: RFA AG 13 016 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 13 008 Funding Number: PAR 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 14 001 Funding Number: RFA GM 14 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) Apply for PAR 13 009 Funding Number: PAR 13 009 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Mentored Research Scientist Development Award in Metabolomics (K01) Apply for RFA RM 12 025 Funding Number: RFA RM 12 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health System Strengthening Project Apply for APS 391 13 000001 Funding Number: APS 391 13 000001 Agency: Pakistan USAID Islamabad Category: Health Funding Amount: $21,900,000 |
| Limited Competition Brain Tissue Resource Center for Alcohol Research (R28) Apply for PAR 13 011 Funding Number: PAR 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiative to Maximize Research Education in Genomics Courses (R25) Apply for PAR 13 012 Funding Number: PAR 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Agir pour la Planification Familiale AGIR PF Apply for RFA 624 13 000002 Funding Number: RFA 624 13 000002 Agency: Ghana USAID Accra Category: Health Funding Amount: $29,000,000 |
| Alzheimers Disease Therapeutics Program (U01) Apply for RFA AG 13 014 Funding Number: RFA AG 13 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epigenomics of Virus Associated Oral Diseases (R21) Apply for RFA DE 13 003 Funding Number: RFA DE 13 003 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epigenomics of Virus Associated Oral Diseases (R01) Apply for RFA DE 13 002 Funding Number: RFA DE 13 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Network for Clinical Research on Immune Tolerance (UM1) Apply for RFA AI 12 043 Funding Number: RFA AI 12 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tuberculosis Research Units (U19) Apply for RFA AI 12 045 Funding Number: RFA AI 12 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Conference Grant Program (R13) Apply for PA 13 017 Funding Number: PA 13 017 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Limited Competition Collaborative Partnership to Advance Global Biomedical Research Programs (U01) Apply for RFA AI 12 055 Funding Number: RFA AI 12 055 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Age Related Changes in Osteoimmunology (R01) Apply for RFA AG 13 017 Funding Number: RFA AG 13 017 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| FY13 FY14 Department of Defense HIV/AIDS Prevention Program Military Specific HIV/AIDS Prevention, Care, and Treatment Program for non PEPFAR (Presidents Emergency Plan for AIDS Relief) Funded Countries Apply for DHAPP BAA 13 001 Funding Number: DHAPP BAA 13 001 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Tuskegee, Alabama Apply for HRSA 13 260 Funding Number: HRSA 13 260 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,398,873 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 13 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.